Terms: = Colorectal cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
4357 results:
1. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract] [Full Text] [Related]
2. Emerging trends in gastrointestinal cancers: Targeting developmental pathways in carcinogenesis and tumor progression.
Ahmad A; Tiwari RK; Siddiqui S; Chadha M; Shukla R; Srivastava V
Int Rev Cell Mol Biol; 2024; 385():41-99. PubMed ID: 38663962
[TBL] [Abstract] [Full Text] [Related]
3. Genomic landscape of diploid and aneuploid microsatellite stable early onset colorectal cancer.
Zhou Y; Chen X; Chen J; Kendrick CD; Ramanathan RK; Graham RP; Kossick KF; Boardman LA; Barrett MT
Sci Rep; 2024 Apr; 14(1):9368. PubMed ID: 38654044
[TBL] [Abstract] [Full Text] [Related]
4. [Chinese expert consensus on maintenance treatment with anti-egfr monoclonal antibody for
Committee of Colorectal Experts, Chinese Society of Clinical Oncology
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):316-325. PubMed ID: 38644236
[TBL] [Abstract] [Full Text] [Related]
5. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
6. A phenotypic screening approach to target p60AmotL2-expressing invasive cancer cells.
Fonseca P; Cui W; Struyf N; Tong L; Chaurasiya A; Casagrande F; Zhao H; Fernando D; Chen X; Tobin NP; Seashore-Ludlow B; Lundqvist A; Hartman J; Göndör A; Östling P; Holmgren L
J Exp Clin Cancer Res; 2024 Apr; 43(1):107. PubMed ID: 38594748
[TBL] [Abstract] [Full Text] [Related]
7. Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with egfr and YBX-1.
Zhou X; Zhang K; Wang C; Teng Y; Yu P; Cai W; Gao W; Li M; Ding Y; Sun P; Chen F; Wang Y; Ma J; Maeshige N; Ma X; Li Q; Liang X; Zhang Y; Su D
Cancer Lett; 2024 May; 590():216868. PubMed ID: 38593920
[TBL] [Abstract] [Full Text] [Related]
8. Anti-egfr Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic colorectal cancer: A Nonrandomized Controlled Trial.
Ciardiello D; Martinelli E; Troiani T; Mauri G; Rossini D; Martini G; Napolitano S; Famiglietti V; Del Tufo S; Masi G; Santini D; Avallone A; Pietrantonio F; Lonardi S; Di Maio M; Zampino MG; Fazio N; Bardelli A; Siena S; Cremolini C; Sartore-Bianchi A; Ciardiello F
JAMA Netw Open; 2024 Apr; 7(4):e245635. PubMed ID: 38592721
[TBL] [Abstract] [Full Text] [Related]
9. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
10. Indoxyl sulfate contributes to colorectal cancer cell proliferation and increased egfr expression by activating AhR and Akt.
Ichisaka Y; Yano S; Nishimura K; Niwa T; Shimizu H
Biomed Res; 2024; 45(2):57-66. PubMed ID: 38556263
[TBL] [Abstract] [Full Text] [Related]
11. Unveiling Prognostic RNA Biomarkers through a Multi-Cohort Study in colorectal cancer.
Kim Z; Lee J; Yoon YE; Yun JW
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542291
[TBL] [Abstract] [Full Text] [Related]
12. Targeting
Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
[TBL] [Abstract] [Full Text] [Related]
13. Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment.
Zhou YW; Zhao X; Ni L; Cao P; Leng WB; Zhu Q; Gou HF; Zhang J; Li XF; Qiu M
Int Immunopharmacol; 2024 Apr; 131():111887. PubMed ID: 38503018
[TBL] [Abstract] [Full Text] [Related]
14. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract] [Full Text] [Related]
15. [History and Perspective of Chemotherapy in Advanced Esophageal cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract] [Full Text] [Related]
16. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor (egfr) is a target of the tumor-suppressor E3 ligase FBXW7.
Boretto M; Geurts MH; Gandhi S; Ma Z; Staliarova N; Celotti M; Lim S; He GW; Millen R; Driehuis E; Begthel H; Smabers L; Roodhart J; van Es J; Wu W; Clevers H
Proc Natl Acad Sci U S A; 2024 Mar; 121(12):e2309902121. PubMed ID: 38483988
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A; Cenigaonandia-Campillo A; García-Bautista A; Mateos-Gómez PA; Schlaepfer MI; Del Puerto-Nevado L; Aguilera O; García-García L; Galeano C; de Miguel I; Serrano-López J; Baños N; Fernández-Aceñero MJ; Lacal JC; Medico E; García-Foncillas J; Cebrián A
Br J Cancer; 2024 May; 130(8):1402-1413. PubMed ID: 38467828
[TBL] [Abstract] [Full Text] [Related]
19. Stage at diagnosis of colorectal cancer in the Middle East and Northern Africa: A population-based cancer registry study.
Znaor A; Eser S; Bendahhou K; Shelpai W; Al Lawati N; ELBasmi A; Alemayehu EM; Tazi MA; Yakut C; Piñeros M
Int J Cancer; 2024 Jul; 155(1):54-60. PubMed ID: 38456478
[TBL] [Abstract] [Full Text] [Related]
20. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
[TBL] [Abstract] [Full Text] [Related]
[Next]
